InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
Product | Citation | Year | Journal | Authors | Page |
---|---|---|---|---|---|
LPS-EB Biotin | Leishmania Lipophosphoglycan Triggers Caspase-11 and the Non-canonical Activa... | 2019 | Cell Rep. | de Carvalho R.V.H. et al. | DOI: 10.1016/j.celrep.2018.12.047 |
Primocin® | Correlation of in vitro cell adhesion, local shear flow and cell density. | 2019 | RSC Adv. | Jötten A.M. et al. | DOI: 10.1039/C8RA07416J |
Plasmocin® - Mycoplasma Elimination Reagent | Automated Detection of Autophagy Response Using Single Cell-Based Microscopy ... | 2019 | Methods Mol Biol. | Mueller A.J. & Proikas-Cezanne T. | DOI: 10.1007/978-1-4939-8873-0_27 |
PlasmoTest™ - Mycoplasma Detection Kit | SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target. | 2019 | Nat Commun. | Yuan S. et al. | DOI: 10.1038/s41467-018-08015-x |
Puromycin | The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism a... | 2019 | Oncogene | Parzych K. et al. | DOI: 10.1038/s41388-018-0651-z |
EndoFit™ OVA protein | Corn-derived alpha-D-glucan nanoparticles as adjuvant for intramuscular and i... | 2019 | Nanomedicine. | Dhakal S. et al. | DOI: 10.1016/j.nano.2018.12.003 |
R848 (Resiquimod) | Impact of polymer-TLR-7/8 agonist (adjuvant) morphology on the potency and me... | 2019 | Biomacromolecules. | Lynn GM. et al. | DOI: 10.1021/acs.biomac.8b01473 |
Normocin® - Antimicrobial Reagent | Impact of polymer-TLR-7/8 agonist (adjuvant) morphology on the potency and me... | 2019 | Biomacromolecules. | Lynn GM. et al. | DOI: 10.1021/acs.biomac.8b01473 |
Imiquimod VacciGrade™ (R837) | Impact of polymer-TLR-7/8 agonist (adjuvant) morphology on the potency and me... | 2019 | Biomacromolecules. | Lynn GM. et al. | DOI: 10.1021/acs.biomac.8b01473 |
Imiquimod (R837) | Impact of polymer-TLR-7/8 agonist (adjuvant) morphology on the potency and me... | 2019 | Biomacromolecules. | Lynn GM. et al. | DOI: 10.1021/acs.biomac.8b01473 |
QUANTI-Blue™ | Impact of polymer-TLR-7/8 agonist (adjuvant) morphology on the potency and me... | 2019 | Biomacromolecules. | Lynn GM. et al. | DOI: 10.1021/acs.biomac.8b01473 |
Human TLR7 Reporter HEK293 Cells (NF-κB) | Impact of polymer-TLR-7/8 agonist (adjuvant) morphology on the potency and me... | 2019 | Biomacromolecules. | Lynn GM. et al. | DOI: 10.1021/acs.biomac.8b01473 |
R848 VacciGrade™ | Impact of polymer-TLR-7/8 agonist (adjuvant) morphology on the potency and me... | 2019 | Biomacromolecules. | Lynn GM. et al. | DOI: 10.1021/acs.biomac.8b01473 |
ASC-GFP Reporter Monocytes | The Crohn's Disease Risk Factor IRGM Limits NLRP3 Inflammasome Activation by ... | 2019 | Mol Cell. | Mehto S. et al. | DOI: 10.1016/j.molcel.2018.11.018 |
Poly(I:C) (LMW) / LyoVec™ | The Crohn's Disease Risk Factor IRGM Limits NLRP3 Inflammasome Activation by ... | 2019 | Mol Cell. | Mehto S. et al. | DOI: 10.1016/j.molcel.2018.11.018 |
MDP | The Crohn's Disease Risk Factor IRGM Limits NLRP3 Inflammasome Activation by ... | 2019 | Mol Cell. | Mehto S. et al. | DOI: 10.1016/j.molcel.2018.11.018 |
Poly(dA:dT) | The Crohn's Disease Risk Factor IRGM Limits NLRP3 Inflammasome Activation by ... | 2019 | Mol Cell. | Mehto S. et al. | DOI: 10.1016/j.molcel.2018.11.018 |
MSU Crystals | The Crohn's Disease Risk Factor IRGM Limits NLRP3 Inflammasome Activation by ... | 2019 | Mol Cell. | Mehto S. et al. | DOI: 10.1016/j.molcel.2018.11.018 |
ATP | The Crohn's Disease Risk Factor IRGM Limits NLRP3 Inflammasome Activation by ... | 2019 | Mol Cell. | Mehto S. et al. | DOI: 10.1016/j.molcel.2018.11.018 |
Bafilomycin A1 | The Crohn's Disease Risk Factor IRGM Limits NLRP3 Inflammasome Activation by ... | 2019 | Mol Cell. | Mehto S. et al. | DOI: 10.1016/j.molcel.2018.11.018 |